Contact lens that can deliver glaucoma treatment


Wednesday, 18 May, 2022

Contact lens that can deliver glaucoma treatment

International researchers have developed a contact lens that is said to be capable of treating glaucoma by sensing when treatment is required and applying it.

The device is flexible and battery-free, with a compact design, and may be a promising system for the treatment of glaucoma, according to the researchers. While further research is needed, the team says this device could one day be manufactured cost-effectively. Glaucoma, and its associated diseases, can cause irreversible vision loss, with damage often caused by an increase of intraocular pressure due to the abnormal circulation of fluid within the eye.

This pressure can vary with human activities and circadian rhythm, which makes treatment challenging as it requires the long-term and continuous tracking of the eye’s condition. Theranostic devices — which combine therapeutics and diagnostics — are capable of monitoring a determined condition and applying an appropriate treatment.

Xi Xie, Cheng Yang and colleagues developed a theranostic contact lens, which uses electrical sensing to measure intraocular pressure and can deliver a drug on demand. The device was tested in porcine and rabbit eyes and was able to detect changes in intraocular pressure. When the measured intraocular pressure reaches a high-risk level, the drug delivery module (powered by wireless power transfer) has the ability to trigger delivery of an anti-glaucoma drug into the anterior chamber of the eye across corneal barriers.

The authors suggest that fabrication of the device is compatible with existing large-scale and cost-effective manufacturing processes. However, they indicate that further research is needed before it can move towards clinical tests.

Image credit: ©stock.adobe.com/au/Анна Ковальчук

Related News

Non-invasive 'virtual' biopsy for skin cancer diagnosis

Researchers have developed a new imaging method that allows clinicians to analyse the skin...

UTI vaccines could prevent infection for nine years

MV140 is a new vaccine for recurrent UTIs and is administered with two sprays of a...

What's the key to retaining rural GPs?

Understanding doctors' decisions to stay or leave, once recruited, could provide insights on...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd